Novogen appoints Iain Ross acting CEO, reappoints him to board
Monday, July 27, 2015
Novogen, a U.S.-Australian drug development company, has reappointed Iain Ross to the board. Ross, a former director of Novogen, also will become acting chief executive until a permanent appointment is made.
Ross currently is chairman of Premier Veterinary Group (formerly Ark Therapeutics), a non-executive director of Amarantus Biosciences and a non-executive director for ASX-listed companies Anatara Lifesciences, Benitec Biopharma and Tissue Therapies.
Following a career with multinational companies Sandoz, Hoffman La Roche and Celltech Group, Ross has over the past 20 years undertaken a number of company startups, turnarounds and exits as a board member on behalf of private equity groups and banks. These include Quadrant Healthcare (sold to Elan); Eden BioDesign (sold to Watson Pharmaceuticals); Phadia (sold to Cinven); SR Pharma (merged with Atugen to form Silence Therapeutics); Allergy Therapeutics (prepared for IPO); and Ark Therapeutics.